Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
CSX Outlook Supported by Cost Cuts, Pricing as Savings Slow, UBS Says

CSX Outlook Supported by Cost Cuts, Pricing as Savings Slow, UBS Says

MT newswireMT newswire2026/10/22 17:12
01:12 PM EDT, 10/22/2026 (MT Newswires) -- CSX (CSX) has meaningful cost savings drivers in 2027 and should benefit from stronger pricing overall, even as the savings from cost cuts get smaller, UBS said in a note Thursday. CSX reported Q3 earnings per share of $0.57, above UBS's $0.54 estimate and the $0.53 consensus estimate, and UBS raised its 2027 EPS estimate to $2.42 from $2.33, according to the note. CSX plans about 100 productivity initiatives in 2027, but the company expects savings to be smaller than in 2026 after this year's big overhead cuts, UBS noted. The firm sees crew scheduling and maintenance automation to be meaningful cost savings drivers for the company in 2027, according to the note. Intermodal volumes rose 6.8% in Q3 and new services and higher truckload rates should drive more growth in 2027, along with pricing gains that begin in Q2 and build through Q3, UBS said. UBS kept its buy rating and raised its price target to $60 from $54, citing productivity gains, stronger pricing and volume growth. Price: 51.85, Change: +3.45, Percent Change: +7.13
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny

CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.

智通财经•2026/11/09 06:37
CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny